Windlas Biotech Limited
Bandhan Mutual Fund has slipped off the disclosed shareholder list for Windlas Biotech Limited this quarter, having either fully exited the previous 1.43 percent stake or trimmed the holding below the 1 percent reporting threshold.
A leading pharmaceutical contract development and manufacturing organization, Windlas Biotech specializes in producing solid and liquid dosage forms for domestic and international clients. The company provides comprehensive CDMO services including product discovery, development, and commercial manufacturing of generic and complex generic medications. Its vertically integrated operations, technical capabilities, and focus on quality manufacturing distinguish it within India's pharmaceutical sector.
Formerly IDFC Mutual Fund, rebranded after Bandhan Financial Holdings acquired IDFC's AMC in 2023. Manages over Rs 1.5 lakh crore. Known for strong debt and liquid funds, plus well-regarded equity offerings including the IDFC-lineage Sterling Value Fund and Focused Equity Fund. One of the cleaner transitions in Indian AMC ownership history.